Navigating the storm: a young woman’s battle with refractory lupus nephritis complicated by pulmonary tuberculosis: a detailed case report
DOI:
https://doi.org/10.18203/2320-6012.ijrms20252942Keywords:
Lupus nephritis, Systemic lupus erythematosus, TuberculosisAbstract
Systemic lupus erythematosus (SLE) is an autoimmune disease that is commonly treated with high dose of corticosteroids and other immunosuppressive medications. Patients with SLE are thus more likely to become infected with a variety of pathogens, including Mycobacterium tuberculosis. There are no established guidelines for treatment of tuberculosis in SLE patients with high disease activity due to a lack of relevant studies and management based on physician expertise. This article presents a case report of a 31 years old female with underlying SLE and refractory lupus nephritis previously treated with IV methylprednisolone pulse therapy and 6 doses of cyclophosphamide and Rituximab presented with Fever, cough with expectoration, pain abdomen and loose stools for a 15 days duration. Mini-BAL CBNAAT detected TB. She was treated with intravenous methylprednisolone and anti-tuberculous therapy, but the result was a fatal outcome.
Metrics
References
Ward MM, Pyun E, Studenski S. Causes of death in systemiclupus erythematosus: long-term followup of an inceptioncohort. ArthritRheum. 1995;38:1492–9. DOI: https://doi.org/10.1002/art.1780381016
Tam LS, Li EK, Wong SM, Szeto CC. Risk factors and clinicalfeatures for tuberculosis among patients with systemiclupus erythematosus in Hong Kong. Scand J Rheumatol. 2002;31:296–300. DOI: https://doi.org/10.1080/030097402760375205
Falagas ME, Voidonikola PT, Angelousi AG. Tuberculosis inpatients with systemic rheumatic or pulmonary diseasestreated with glucocorticosteroids and the preventive role ofisoniazid: a review of the available evidence. Int J Antimicrob Agents. 2007;30:477–86. DOI: https://doi.org/10.1016/j.ijantimicag.2007.07.010
Ghosh K, Patwardhan M, Pradhan V. Mycobacterium tubercu-losis infection precipitates SLE in patients from endemicareas. Rheumatol Int. 2009;29:1047–50. DOI: https://doi.org/10.1007/s00296-009-0903-x
World Health Organization. Guidelines on the management of latent tuberculosis infection. World Health Organization. 2015.
Wu Q, Liu Y, Wang W, Zhang Y, Liu K, Chen SH, et al. Incidence and prevalence of tuberculosis in systemic lupus erythematosus patients: A systematic review and meta-analysis. Front Immunol. 2022;13:4678. DOI: https://doi.org/10.3389/fimmu.2022.938406
Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MPR. The immune response in tuberculosis. Ann Rev Immunol. 2013;31(1):475–527. DOI: https://doi.org/10.1146/annurev-immunol-032712-095939
Feng PH, Tan TH. Tuberculosis in patients with systemic lupus erythematosus. Ann Rheum Dis. 1982;41(1):11–4. DOI: https://doi.org/10.1136/ard.41.1.11
Agrawal S, Prabu VNN. Systemic lupus erythematosus and tuberculosis: A review of complex interactions of complicated diseases. J Postgrad Med. 2010;56(3):244. DOI: https://doi.org/10.4103/0022-3859.68653
Bozinovic F, Calosi P, Spicer JI. Physiological correlates of geographic range in animals. Ann Rev Ecol, Evol System. 2011;42(1):155–79. DOI: https://doi.org/10.1146/annurev-ecolsys-102710-145055
Downloads
Published
How to Cite
Issue
Section
